Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy.
about
Re-configuration of sphingolipid metabolism by oncogenic transformation.Racotumomab-alum vaccine for the treatment of non-small-cell lung cancer.Investigations on aberrant glycosylation of glycosphingolipids in colorectal cancer tissues using liquid chromatography and matrix-assisted laser desorption time-of-flight mass spectrometry (MALDI-TOF-MS).Ganglioside biochemistrySystems toxicology approaches enable mechanistic comparison of spontaneous and cigarette smoke-related lung tumor development in the A/J mouse model.Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8Stage-specific embryonic antigen-4 as a potential therapeutic target in glioblastoma multiforme and other cancers.Novel chemotherapeutic drugs in sphingolipid cancer research.Antibody recognition of carbohydrate epitopes†.The sweet side of tumor immunotherapy.Sphingolipids: key regulators of apoptosis and pivotal players in cancer drug resistanceChemoenzymatic Syntheses of Sialylated Oligosaccharides Containing C5-Modified Neuraminic Acids for Dual Inhibition of Hemagglutinins and Neuraminidases.A platform for the structural characterization of glycans enzymatically released from glycosphingolipids extracted from tissue and cells.A shift from N-glycolyl- to N-acetyl-sialic acid in the GM3 ganglioside impairs tumor development in mouse lymphocytic leukemia cells.Natural Killer T Cells in Cancer ImmunotherapySphingadienes show therapeutic efficacy in neuroblastoma in vitro and in vivo by targeting the AKT signaling pathway.Broadening the translational immunology landscape.Serum sialylation changes in cancer.
P2860
Q33649823-F9CC5800-1413-4A4C-8CC0-48E14751B603Q34449304-836C5738-98D9-480C-8F3F-8B0ADDE9EB0CQ34859119-898B24B4-1296-4F57-9D98-18A656D93A1CQ35361488-4249DC1E-CB90-437F-9A5A-6382664871FDQ35594350-45EEA758-1EA9-46DE-8028-C8AE049FEC05Q35860917-1F19EC28-1D8F-4D4D-ACF5-AF96710B53C5Q37599805-BFCE7B1C-AFFC-47A4-84ED-86755DD67151Q37721276-53585CF1-8F8C-406C-B440-3BA8B15E208AQ37840398-351BC590-73C1-456F-9879-DE9AC0803F85Q38031282-7BBDFF2C-F058-4419-9069-821BA26DC042Q38195691-E05E94EB-7BF3-4AC6-A956-8F22236E4C1AQ38298211-A56DE0CC-DEB0-4CD4-A646-FB79079CE3AFQ38849130-45AF9245-9D88-41F8-92E7-E627FAE5E66AQ39172701-FBEAFF9C-7AEF-4C51-94AE-C51B22DE7311Q42078314-45DD3867-A6B6-48FA-9208-44D80D6F62E5Q50041639-38242E20-F990-421A-94DE-E5B9D0FF1A02Q50777385-714F2F6B-BC8A-4E65-ABB9-46FD032D9C2FQ55410162-7AA85F3A-DF93-47B4-B7C1-28B8DBD552EF
P2860
Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Immunology in the clinic revie ...... gets for tumour immunotherapy.
@en
Immunology in the clinic revie ...... gets for tumour immunotherapy.
@nl
type
label
Immunology in the clinic revie ...... gets for tumour immunotherapy.
@en
Immunology in the clinic revie ...... gets for tumour immunotherapy.
@nl
prefLabel
Immunology in the clinic revie ...... gets for tumour immunotherapy.
@en
Immunology in the clinic revie ...... gets for tumour immunotherapy.
@nl
P2860
P1476
Immunology in the clinic revie ...... gets for tumour immunotherapy.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2249.2011.04516.X
P577
2012-02-01T00:00:00Z